The natural viral load profile of patients with pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment

Chest

Volumn 137, Issue 4, 2010, Pages 759-768

  Li, Iris W ^a   Hung, Ivan F ^a   To, Kelvin K ^a   Chan, Kwok Hung ^a   Wong, Samson S Y ^a   Chan, Jasper F ^a   Cheng, Vincent C ^a   Tsang, Owen T ^b   Lai, Sik To ^b   Lau, Yu Lung ^a   Yuen, Kwok Yung ^a  

^a PRINCESS MARGARET HOSPITAL   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR;

ADOLESCENT; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFECT; FEMALE; FEVER; HONG KONG; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NASOPHARYNGEAL ASPIRATION; PANDEMIC; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; VIRUS LOAD;

EID: 77950826918     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-3072     Document Type: Article

References (48)

1. World Health Organization. Human infection with new influenza A (H1Nl) virus: clinical observations from Mexico and other affected countries, May 2009. Wkly/ Epidemiol Rec. 2009:84(21):185-189.
2. World Health Organization. Statement to the press by WHO Director-General Dr Margaret Chan June 11, 2009. World now at the start of 2009 influenza pandemic. http:/www. who.int/mediacentre/news/staternents/2009/h1n1-pandomic- phaso6-20090611/en/index.html, Accessed August 3, 2009.
3. Centers for Disease Control and Prevention (CDC). Update: novel influenza A (HlNl) virus inlection-Mexico, March-May. 2009. MMWR Morb Mortal Wkly Rep. 2009;58(21):585-589.
4. Hancock K, Voguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009:381(20):1945-1952.
5. Maines TR, Jayaraman A. Belser JA, et al. Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science. 2009;325(5939):484-487.
6. Munster VJ, de Wit K, van den Brand JMA, et al. Pathogenesis and transmission of swine-origin 2009 A(HlNl) influenza virus in ferrets. Science. 2009; 325(5939): 481-483.
7. Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin HlNl influenza virus. Nature, 2009; 4, 59(7249): 931-939.
8. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S. et al; INER Working Group on Influenza. Pneumonia and respiratory failure from swine-origin influenza A (HlNl) in Mexico. 'N Engl J Med. 2009: 361 (7): 680-689.
9. World Health Organization. WHO Guidelines for pharmacological management of pandemic (H1N1) 2009 influenza and other influenza virus. 20 Aug 2009. http://www.who. int/esr/resourees/publications/swineflu/hln]-guidelines- pharmaceutical-mngt.pdf. Accessed November 30. 2009.
10. Hospital Authority. Hong Kong SAR. HA Central Committee on Infectious Disease and Emergency Responses (CClDER). Interim guidance on antiviral treatment, chemoprophylaxis and pneumococcal vaccination for human swine influenza (HSI)/ influenza A (H1N1) infection. http:/Av\vw.ha.org.hk/haho/ho/ hsflu/lnterim-Treatment.pdf. Accessed August 5, 2009.
11. Centers for Disease Control and Prevention. CDC Health Alert Network (HAN) Info Sendee Message: Three reports of oseltamivir-resistant novel influenza A (H1K1) viruses. http://www.cdc.gov/h1n1flu/H AN/070909, htm. Accessed August 3, 2009.
12. Wong SS, Yuen KY. Avian influenza virus infections in humans. Chesl. 2006; 129(1): 156-168.
13. Nicholson KG, Aoki FY, Oslerhaiis AD. el al; Neuraminidase Inhibitor Flu Treatment Investigator Group. Ffflcacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial, Lancet, 2000; 355(9218): 1845-1850.
14. Wong SS, Yuen KY. Antiviral therapy for respiratory tract infections. Hespirology. 2008; 13(7): 950-971.
15. Jefferson T, Jones M, Doshi P. Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review mid meta-analysis. BMJ. 2009; 339: b5106.
16. Food and Health Bureau. The Government of the H ongKong SAR. Legislative Council Panel on Health Services. Prevention and control of human swine influenza infection in Hong Kong. http://\v\vw.legco.gov.hk/\T08-09/english/ panels/hs/papers/hs0511cb2-1505- 1-e.pdf. Accessed August 3, 2009.
17. Centre for Health Protection, Department of Health, Hong Kong SAR. Strategy and management of human swine influenza (HSI). http://wwvv.chp.gov.hk/ files/pdf/Strategy-swine-flu-20090512-F.ng.pdf. Accessed August 3. 2009.
18. Hospital Authority. I long Kong SAR. HA Central Committee on Infectious Disease and Emergency Responses (CClDKR), Interim guidance on antiviral treatment, chemoprophylaxis and pneumococcal vaccination for human swine influenza (HSI) / influenza A (H1N1 ) infection, http://www.ha.org.hk/halio/ho/ hsflu/lnterim-Treatment.pdf. Accessed August 5. 2009.
19. Cheng VC. Hung IF. Tang BS, et al. Viral replication in the nasopharynx is associated with diarrhea in patients with severe acute respiratory syndrome. Clin Infect Dis. 2004: 38(4): 467-475. (Pubitemid 38250954)
20. Boivin G, Hardy I. Tellier G, Maziade |. Predicting influenza infections during epidemics with use of a clinical case definition. Clin Infect Dis. 2000; 31(5): 1166-.1169. (Pubitemid 32295445)
21. Zambon M, Hays J, Webster A, Newman R, Keene O. Diagnosis of influenza in the community: relationship ol clinical diagnosis to confirmed virological, serologic, or molecular detection of influenza. Arch Intern Med. 2001; 181(17): 2116-2122. (Pubitemid 36231507)
22. Chan KH, Yam WC, Pang CM, et al. Comparison of the KucliSens easyMAG mid Qiagen BioRobot 9604 nucleic acid extraction systems for detection of RNA and DKA respiratory viruses in nasopharyngeal aspirate samples. J Clin Microbiol, 2008; 46(7): 2195-2199
23. To KK, Chan KH, Li IW. et al. Viral load in patients infected with pandemic H1N1 2009 influenza A virus. J Med Virol. 2010; 82(1): l-7.
24. Cheng VC, Tang BS. Wu AK, Chu CM, Yuen KY. Medical treatment of viral pneumonia including SARS in immunocompetent adult. J Infect. 2004; 49(4): 262-273.
25. Centers for Disease Control and Prevention (CDC). CDC Realtime RT-PCR (rRTPCR) protocol for detection and characterization of influenza (version 2007). CDC REF. # 1-007-105
26. Li IW, Chan KH. To KW . et al, Differential susceptibility of different cell lines to sv. iue-origin influenza A H1N1. seasonal human influenza A H1N1 ,and avian influenza A H5N1 viruses J Clin Virol. 2009: 46(4): 325-330.
27. Havden FG, Treanor JJ. Fritz RS. et al. Use of the oral neuraminidase inhibitor osellamivir in experimental human influenza: randomized controlled trials for prevention and treatment, JAMA. 1999; 282( 13): 1240-1246.
28. Sato M. Hosoya M, Kato K, Suzuki 11, Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors. Pediatr inject Dis. 2005; 24(10): 931-932. (Pubitemid 41475935)
29. Meijer A, Lackenby A, Hungnes O, et al; European Influenza Surveillance Scheme. Osellamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season, Emerg Infect Dis. 2009; 15(4): 552-560.
30. de Jong MD, Tran TT, Truoiig HK. et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005: 353(25): 2667-2672.
31. Yuen KY. Chan PK, Peiris M. et al, Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancei. 1998: 351(9101 ): 467-471. (Pubitemid 28070092)
32. Kiso M, Mitamura K, Sakai-Tagawa Y. et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancei. 2004; 364(9436): 759-765. (Pubitemid 39165094)
33. Hange SH, Dudmari S, Borgen K. Lacken by A, Hungnes O, Oseltamivir-resistanl influenza viruses A (HINl), Norway, 2007-2008. Emerg Infect Dis. 2009; 15(2): 155-162.
34. Centers for Disease Control and Prevention (CDC), Update: drug susceptibility of swine-origin influenza A (H1N1) vinises, April 2009. MMWR Morb Mortal WkIy Rep. 2009: 58(16): 433-435.
35. Kawai N. Ikematsu H, Hirotsu N, et al. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons. Clin Infect Dis. 2009; 49(12): 1823-1835.
36. Chen H, Cheung CL, Tai H, et al, Oscltamivir-rcsistarit influenza A pandemic (H1N1) 2009 virus. Hong Kong, China. Emerg infect Dk. 2009; 15(12): 1970-1972.
37. JegerlehnerA,SchmitzN,StorniT,BachmannMF. InfluenzaAvaccinebasedontheextracellulardomainofM2: weakprotectionmediatedviaantibody-dependentNKcellactivity.Immunol.2004;172(9): 5598-5605.(Pubitemid38542062)
38. Cheng VCC, Lan YK, Lee KL, et al. Fatal co-infection with swine origin infli lenza vin is .A/H1N1 and community-acqi iired methicillinresistant Staphylococcus aureus. J. Infect. 2009; 59(5): 366-370.
39. Wong SS, Yuen KY. The severe acute respiratory syndrome (SARS)./ Netiroviroi. 2005; 11(5): 455-468. (Pubitemid 43064685)
40. Hung IF, Cheng VC, Wu AK, et al. Viral loads in clinical specimens and SARS manifestations. Emerg Infect Dis. 2004; 10(9): 1550-1557.
41. Zhou J. Law HK, Cheung CY, Ng LH, Peiris JS, Lau YL. Functional tumor necrosis faetor-refated apoptosis-inducing ligand production by avian influenza virus-infected macrophages, J infect Dis. 2006; 193(7): 945-953.
42. Miller RR III, Markewitz RA, Rolfs RT et al. Clinical findings and demographic factors associated with intensive care unit admission in Utah due to novel 2009 influenza A(H1N1) infection. Chest. 2010; 137(4): 752-758.
43. Centers for Disease Control and Prevention (CDC). Hospitalized patients with novel influenza A (H1N1) virus infection - California, April - May, 2009. MMWR Morb Mortal Wkly Rep. 2009; 58(19): 536-541.
44. Gooskens J. Jonges M, Claas EC. Meijer A, Kroes AC. Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses. J Infect Dis. 2009; 199(10): 1435-1441.
45. Daley P. Castriciano S, Chornesky M, Smieja VI. Comparison of flocked and rayon swabs for collection of respiratory epithelial cells lrom uninfected volunteers and symptomatic patients. J Clin Microbiol. 2006; 44(6): 2265-2267. (Pubitemid 43902191)
46. Kitching A, Roche A, Balasegaram S, Heathcock R, Maguire H, Oseltamivir adherence and side effects among children in three London schools affected by influenza A(H1N1)v, May 2009 - an internet-based cross-sectional survey. Euro Surveill. 2009; 14(30): 19287. http://www.eurosurveillance.org/ViewArticle. aspxPArticIeld= 19287.
47. Toovey S. Rayner C, Prinssen K. et al. Assessment of neuropsychiatrie adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saj, 2008; 31(12): 1097-1114.
48. Huang YC, Li WC, Tsao KC, Huang CCh,Chin CH, Lin TY. Influenza associated central nervous system dysfunction in Taiwanese children: clinical characteristics and outcomes with and without administration of oseltamivir. Pediatr Infect Dis J. 2009; 28(7): 647-648.